Novacyt (ALNOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novacyt (ALNOV) has a cash flow conversion efficiency ratio of -0.141x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.28 Million ≈ $-3.84 Million USD) by net assets (€23.34 Million ≈ $27.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Novacyt fund operations to measure how many days the company can operate on defensive assets alone.
Novacyt - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Novacyt's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novacyt Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novacyt ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Co2 Capsol AS
OL:CAPSL
|
-0.204x |
|
Kartal Yenilenebilir Enerji Uretim AS
IS:KARYE
|
-0.059x |
|
Freemelt Holding AB
ST:FREEM
|
-0.037x |
|
Mindax Ltd
AU:MDX
|
-0.040x |
|
Avonmore Capital & Management Services Limited
NSE:AVONMORE
|
0.002x |
|
Manx Financial Group PLC
F:3IM
|
-0.264x |
|
KNW Co. Ltd
KQ:105330
|
0.026x |
|
Fusemachines Inc. Common stock
NASDAQ:FUSE
|
1.481x |
Annual Cash Flow Conversion Efficiency for Novacyt (2010–2025)
The table below shows the annual cash flow conversion efficiency of Novacyt from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Novacyt (ALNOV) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €23.34 Million ≈ $27.29 Million |
€-8.76 Million ≈ $-10.24 Million |
-0.375x | -82.93% |
| 2024-12-31 | €47.88 Million ≈ $55.98 Million |
€-9.82 Million ≈ $-11.48 Million |
-0.205x | +28.38% |
| 2023-12-31 | €87.24 Million ≈ $102.00 Million |
€-24.99 Million ≈ $-29.22 Million |
-0.286x | -140.40% |
| 2022-12-31 | €115.22 Million ≈ $134.70 Million |
€-13.73 Million ≈ $-16.05 Million |
-0.119x | -207.71% |
| 2021-12-31 | €141.81 Million ≈ $165.80 Million |
€15.69 Million ≈ $18.34 Million |
0.111x | -83.81% |
| 2020-12-31 | €150.71 Million ≈ $176.20 Million |
€102.98 Million ≈ $120.39 Million |
0.683x | +1029.33% |
| 2019-12-31 | €12.47 Million ≈ $14.58 Million |
€-916.70K ≈ $-1.07 Million |
-0.074x | -18.83% |
| 2018-12-31 | €18.15 Million ≈ $21.22 Million |
€-1.12 Million ≈ $-1.31 Million |
-0.062x | +66.82% |
| 2017-12-31 | €22.12 Million ≈ $25.86 Million |
€-4.12 Million ≈ $-4.82 Million |
-0.186x | -29.43% |
| 2016-12-31 | €15.15 Million ≈ $17.71 Million |
€-2.18 Million ≈ $-2.55 Million |
-0.144x | +71.63% |
| 2015-12-31 | €7.77 Million ≈ $9.08 Million |
€-3.95 Million ≈ $-4.61 Million |
-0.508x | -1099.81% |
| 2014-12-31 | €16.04 Million ≈ $18.75 Million |
€-678.92K ≈ $-793.73K |
-0.042x | +90.85% |
| 2013-12-31 | €1.94 Million ≈ $2.27 Million |
€-897.54K ≈ $-1.05 Million |
-0.462x | -236.32% |
| 2012-12-31 | €1.34 Million ≈ $1.57 Million |
€-184.36K ≈ $-215.54K |
-0.138x | -121.29% |
| 2011-12-31 | €-744.73K ≈ $-870.67K |
€-481.00K ≈ $-562.34K |
0.646x | +1707.09% |
| 2010-12-31 | €-846.00K ≈ $-989.06K |
€34.00K ≈ $39.75K |
-0.040x | -- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more